Amyris partnership with BGI a positive, says H.C. Wainwright

Wainwright analyst Amit Dayal affirmed a Buy rating and $15 price target on Amyris, saying he believes the joint venture with Chinese genomics company BGI will further expand Amyris’s international reach and will help Amyris enter into the multi-billion dollar Chinese medicine market

https://bit.ly/2lxLEYS